- March 15, 2022
- Newsletter
- 617-430-5616
Menu
Menu
Menu
Menu
Menu
Menu
Brand Name :
Tibsovo
Synonyms :
Ivosidenib
Class :
Antineoplastics and IDH1 Inhibitor
Dosage Forms & Strengths
Tablet
250mg
500
mg
Orally
once a day
continue the treatment until disease progression or unacceptable toxicity occurs
patients without disease progression or unacceptable toxicity, given the treatment for up to a minimum of 6 months for clinical response
Safety and efficacy not studied
when both drugs are combined, there may be a decreased effect of doravirine by affecting hepatic or intestinal enzyme cyp3a4 metabolism
when both drugs are combined, there may be a decreased effect of fostemsavir by affecting hepatic or intestinal enzyme cyp3a4 metabolism
when both drugs are combined, there may be a decreased effect of lonafarnib by affecting hepatic or intestinal enzyme cyp3a4 metabolism
when both drugs are combined, there may be a decreased effect of lorlatinib by affecting hepatic or intestinal enzyme cyp3a4 metabolism
when both drugs are combined, there may be a decreased effect of mavacamten by affecting hepatic or intestinal enzyme cyp3a4 metabolism
when both drugs are combined, there may be a decreased effect of pacritinib by affecting hepatic or intestinal enzyme cyp3a4 metabolism
ivosidenib: they may diminish the serum concentration of hormonal contraceptives
ivosidenib: they may diminish the serum concentration of hormonal contraceptives
ivosidenib: they may diminish the serum concentration of hormonal contraceptives
ivosidenib: they may diminish the serum concentration of hormonal contraceptives
when both drugs are combined, there may be an increase in qtc interval
may enhance the serum concentration of CYP3A4 inhibitors
may diminish the serum concentration of CYP3A4 Inducers
may diminish the serum concentration of Hormonal Contraceptives
when both drugs are combined, there may be an increased effect of ivosidenib by affecting hepatic or intestinal enzyme cyp3a4 metabolism
when both drugs are combined, there may be a decreased effect of abemaciclib by affecting hepatic or intestinal enzyme cyp3a4 metabolism
when both drugs are combined, there may be a decreased effect of abiraterone by affecting hepatic or intestinal enzyme cyp3a4 metabolism
when both drugs are combined, there may be a decreased effect of acalabrutinib by affecting hepatic or intestinal enzyme cyp3a4 metabolism
when both drugs are combined, there may be a decreased effect of ado-trastuzumab emtansine by affecting hepatic or intestinal enzyme cyp3a4 metabolism
when both drugs are combined, there may be a decreased effect of alfentanil by affecting hepatic or intestinal enzyme cyp3a4 metabolism
when both drugs are combined, there may be an increased QTC interval
when both drugs are combined, there may be a decreased effect of alpelisib by affecting hepatic or intestinal enzyme cyp3a4 metabolism
when both drugs are combined, there may be a decreased effect of alprazolam by affecting hepatic or intestinal enzyme cyp3a4 metabolism
when both drugs are combined, there may be an increased QTC interval
when both drugs are combined, there may be a decreased effect of mestranol by affecting hepatic or intestinal enzyme cyp3a4 metabolism
when both drugs are combined, there may be a decreased effect of metaxalone by affecting hepatic or intestinal enzyme cyp3a4 metabolism
when both drugs are combined, there may be an increased QTC interval
when both drugs are combined, there may be a decreased effect of methylergonovine by affecting hepatic or intestinal enzyme cyp3a4 metabolism
when both drugs are combined, there may be a decreased effect of methylprednisolone by affecting hepatic or intestinal enzyme cyp3a4 metabolism
when both drugs are combined, there may be an increased effect of ivosidenib by affecting hepatic or intestinal enzyme cyp3a4 metabolism
when both drugs are combined, there may be an increased effect of saxagliptin by affecting hepatic or intestinal enzyme cyp3a4 metabolism
when both drugs are combined, there may be a decreased effect of ivosidenib by affecting hepatic or intestinal enzyme cyp3a4 metabolism
when both drugs are combined, there may be a decreased effect of simvastatin by affecting hepatic or intestinal enzyme cyp3a4 metabolism
when both drugs are combined, there may be a decreased effect of siponimod by affecting hepatic or intestinal enzyme cyp3a4 metabolism
when both drugs are combined, there may be a decreased effect of sirolimus by affecting hepatic or intestinal enzyme cyp3a4 metabolism
when both drugs are combined, there may be an increased metabolism of ivosidenib
the ivosidenib interacting with brentuximab has its effect decreased by altering the intestinal or hepatic CYP3A4 enzyme metabolism.
when both drugs are combined, there may be a decreased level of serum concentration of erlotinib
ivosidenib decreases the effect of ixazomib by altering intestinal/hepatic CYP3A4 enzyme metabolism
both lapatinib and ivosidenib increase the QTc interval
CYP3A strong enhancers of the small intestine may reduce the bioavailability of ivosidenib
ivosidenib decreases the effect of gefitinib by altering the intestinal/ hepatic CYP3A4 enzyme metabolism
it will decrease the impact or level of regorafenib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
it increases the effect or level of ruxolitinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
it reduces the concentration of CYP3A4 substrates in serum
it decreases the effect or level of dronabinol by altering the intestinal or hepatic metabolism
may decrease the level by affecting hepatic enzyme CYP2C9 metabolism
may decrease the level by affecting hepatic enzyme CYP2C9 metabolism
may decrease the level by affecting hepatic enzyme CYP2C9 metabolism
it decreases by affecting the hepatic enzyme CYP3A4 metabolism
when both drugs are combined, there may be an increased QTC interval
when both drugs are combined, there may be an increased effect of ivosidenib by affecting hepatic or intestinal enzyme cyp3a4 metabolism
when both drugs are combined, there may be an increased effect of ivosidenib by affecting hepatic or intestinal enzyme cyp3a4 metabolism
when both drugs are combined, there may be a decreased effect of ivosidenib by affecting hepatic or intestinal enzyme cyp3a4 metabolism
when both drugs are combined, there may be an increased effect of ivosidenib by affecting hepatic or intestinal enzyme cyp3a4 metabolism
when both drugs are combined, there may be an increased effect of ivosidenib by affecting hepatic or intestinal enzyme cyp3a4 metabolism
when both drugs are combined, there may be an increased effect of ivosidenib by affecting hepatic or intestinal enzyme cyp3a4 metabolism
when both drugs are combined, there may be an increased effect of ivosidenib by affecting hepatic or intestinal enzyme cyp3a4 metabolism
when both drugs are combined, there may be an increased effect of ivosidenib by affecting hepatic or intestinal enzyme cyp3a4 metabolism
it may enhance the metabolism when combined with oxcarbazepine
it decreases the concentration of CYP3A4 inducers in serum
it decreases the concentration of CYP3A4 inducers in serum
it decreases the concentration of CYP3A4 inducers in serum
it decreases the concentration of CYP3A4 inducers in serum
it decreases the concentration of CYP3A4 inducers in serum
may increase the serum concentration of tamoxifen
the effect of ivosedinib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
may reduce the serum levels of CYP3A4 substrates
may reduce the serum levels of CYP3A4 substrates
may reduce the serum levels of CYP3A4 substrates
may reduce the serum levels of CYP3A4 substrates
may reduce the serum concentration of CYP3A4 substrates
it reduces the concentration of CYP3A4 substrates in serum
May enhance the plasma concentration of CYP3A4 substrates
it decreases the concentration of hormonal contraceptives in serum
Adverse drug reactions:
Frequency defined
>10%
Decreased hemoglobin
Fatigue
Edema
Decreased sodium
Decreased appetite
Leukocytosis
Decreased magnesium
Vomiting
Headache
Chest pain
Increased bilirubin
Increased alanine aminotransferase
Dyspepsia
Decreased weight
<10%
Constipation
Mucositis
Fatigue
Chest pain
Pleural effusion
Diarrhea
Edema
Decreased phosphate
Leukocytosis
Increased uric acid
Decreased potassium
Arthralgia
Decreased sodium
Hypotension
Rash
Decreased appetite
QT prolongation
Dyspnea
Tumor lysis syndrome
Vomiting
Pyrexia
Nausea
Abdominal pain
Myalgia
Neuropathy
<1%
Cough
Pregnancy warnings:
Breastfeeding warnings:
Pregnancy Categories:
Patient Information Leaflet
Generic Name: Ivosidenib (Rx)
Pronounced: I-voh-SIH-deh-nib
Why do we use Ivosidenib?
Ivosidenib is an anticancer drug used to treat Acute myeloid leukemia (AML) in adults with an IDH1 mutation. Ivosidenib is also used as a secondary if other treatments did not work or have stopped working.
ADVERTISEMENT
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
USA – BOSTON
60 Roberts Drive, Suite 313
North Adams, MA 01247
